To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights ...

The combination of amivantamab and lazertinib shows lower EGFR and MET resistance, offering an advantage over osimertinib alone. Personalized treatment strategies are essential, considering resistance ...

BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT ® ...

Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal ...

TKIs under active clinical investigation are mostly derived from quinazoline, and are low molecular weight synthetic molecules that block the magnesium-ATP-binding pocket of the intracellular tyrosine ...

Background: Treatment options for lung cancer patients with epidermal growth factor receptor (EGFR) mutations are limited after tyrosine kinase inhibitor (TKI) resistance. We aimed to evaluate the ...

Resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib given alone or with chemotherapy, remains a common and major barrier to long-term disease control.4 This ...